The way you follow
biotech is about
to change.
New information should change the picture you already have, not make you rebuild it. LUNA7 is being built to carry context forward, separate what matters from what does not, and keep the evidence attached as the picture changes.
For the trial, US-listed biotech only. Clinical, regulatory, company and market evidence, traced back to source.
Private development. Limited details by design.
Come back six weeks later. Ask one question.
What changed?
The answer should start from the picture that was already there, show what is different now, explain what that change affects, and point back to the evidence behind it.
That is the experience LUNA7 is being built around.
Updates are easy. Maintaining the view is hard.
A trial update, filing or management statement is only one fragment. The real work is understanding how it changes everything you already know about the company or programme.
LUNA7 is being built around that second problem.
The research should compound. Not reset.
A biotech company is not a feed.
It is a changing system.
Trials, regulatory decisions, competition, ownership, catalysts and expectations move on different clocks. LUNA7 is being built to keep those states connected, so when one changes, the rest of the picture does not disappear around it.
Confidence should be earned.
- 01
Evidence before confidence
Important claims should trace back to the record. If the evidence is weak, the answer should say so.
- 02
Uncertainty stays visible
Conflicting sources, missing evidence and unresolved questions are not cleaned up simply to make the answer look complete.
- 03
Context survives the update
New information is interpreted against what was already known, rather than treated as an isolated event.
Built for people accountable for a view on biotech.
Investors · Analysts · Portfolio teams · Strategy · Competitive intelligence
Bring us the company you know best.
We want LUNA7 tested against real work, not polished demonstrations.
Bring difficult companies, messy histories, contradictory evidence and questions you already know the answer to. If the system cannot survive that, it is not ready.
Some of what we are building will remain private until the trial begins.
The trial covers US-listed biotech only. Dates still to be confirmed.